Anti-cancer drugs: trials and tribulations in their development

An evening lecture organised jointly by the Royal Society of Chemistry (Central Yorkshire Section) and the Royal Society of Biology (Yorkshire Branch)

The discovery and development of new anti-cancer drugs is a difficult, time consuming and expensive process. The field is littered with disappointment but these failures provide an opportunity to learn and apply this knowledge to the search for new drugs. This lecture will focus on one such example called EO9 (Apaziquone), a drug that is now in phase III clinical trials for non-muscle invasive bladder cancer despite a history of failure in other clinical trials

Light refreshments will be available from 18.00